Figure 5.

Number of Discontinuation Emergent Signs and Symptoms reported by completers stopping treatment with escitalopram (n = 20). The number of new symptoms reported by the 20 patients who completed the study and tapered down the dose of escitalopram at 32 weeks prior to stopping treatment, as assessed using the Discontinuation Emergent Signs and Symptoms (DESS) scale scores.

Wade et al. BMC Psychiatry 2011 11:42   doi:10.1186/1471-244X-11-42
Download authors' original image